David D. Meek's Insider Trades & SAST Disclosures
David D. Meek's most recent trade in Rhythm Pharmaceuticals Inc. was a trade of 200,000 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David D. Meek.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 200,000 | 200,000 | - | - | Stock Options (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 133,350 | 133,350 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 21,250 | 63,750 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 21,250 | 211,177 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 57.22 per share. | 14 Feb 2025 | 9,896 | 201,281 (0%) | 0% | 57.2 | 566,249 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,125 | 194,205 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,125 | 28,250 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.43 per share. | 01 Feb 2025 | 4,278 | 189,927 (0%) | 0% | 59.4 | 254,242 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 27 Aug 2024 | 4,555 | 357,044 (2%) | 0% | 1.4 | 6,514 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 4,555 | 0 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Sale of securities on an exchange or to another person at price $ 2.93 per share. | 27 Aug 2024 | 4,555 | 352,489 (1%) | 0% | 2.9 | 13,353 | Common Stock |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 15,840 | 15,840 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 8,080 | 28,332 (0%) | 0% | 0 | Ordinary Shares | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 5.12 per share. | 13 Jun 2024 | 2,229 | 20,252 (0%) | 0% | 5.1 | 11,412 | Ordinary Shares |
| Cullinan Oncology Inc | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 15,618 | 15,618 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 19 Mar 2024 | 45,494 | 174,605 (0%) | 0% | 39.2 | 1,784,275 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David Meeker P. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 259,000 | 259,000 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | P. David Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 99,000 | 220,099 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Meeker David P. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 85,000 | 85,000 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Meeker David P. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 14,125 | 42,375 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | P. David Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 14,125 | 125,460 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.06 per share. | 01 Feb 2024 | 4,361 | 121,099 (0%) | 0% | 45.1 | 196,507 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 17,060 | 17,060 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 8,700 | 24,771 (0%) | 0% | 0 | Ordinary Shares | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 18.85 per share. | 13 Jun 2023 | 2,290 | 22,481 (0%) | 0% | 18.9 | 43,167 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 19.71 per share. | 27 Feb 2023 | 389 | 16,071 (0%) | 0% | 19.7 | 7,667 | Ordinary Shares |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 229,600 | 229,600 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 56,500 | 56,500 | - | - | Restricted Stock Units | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 151,233 | 151,233 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 89,379 | 151,171 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 17 Jan 2023 | 3,179 | 61,792 (0%) | 0% | 42.4 | 134,715 | Common Stock |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 35,425 | 69,587 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.41 per share. | 19 Dec 2022 | 4,616 | 64,971 (0%) | 0% | 40.4 | 186,552 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 17,810 | 17,810 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,080 | 16,460 (0%) | 0% | 0 | Ordinary Shares | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 16.70 per share. | 28 Feb 2022 | 602 | 7,380 (0%) | 0% | 16.7 | 10,053 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 2,645 | 2,645 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 1,534 | 7,982 (0%) | 0% | 0 | Ordinary Shares | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 56,433 | 56,433 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 34,057 | 34,057 (0%) | 0% | 0 | Common Stock | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 20.17 per share. | 30 Mar 2021 | 10,000 | 111,335 (0%) | 0% | 20.2 | 201,713 | Common Stock |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 37.50 per share. | 02 Mar 2021 | 505 | 6,448 (0%) | 0% | 37.5 | 18,938 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 4,107 | 4,107 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 2,382 | 6,953 (0%) | 0% | 0 | Ordinary Shares | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 220,000 | 220,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 900,000 | 900,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 18,500 | 18,500 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | David P. Meeker | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges